BNTC: Benitec Biopharma Inc. Stock

by  •  • Comments Off on BNTC: Benitec Biopharma Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 253.29
Enterprise Value ($M) 185.45
Book Value ($M) 64.18
Book Value / Share 2.76
Price / Book 3.95
NCAV ($M) 63.74
NCAV / Share 2.75
Price / NCAV 3.97

Profitability (mra)
Return on Invested Capital (ROIC) -0.32
Return on Assets (ROA) -0.98
Return on Equity (ROE) -1.35

Liquidity (mrq)
Quick Ratio 15.01
Current Ratio 15.01

Balance Sheet (mrq) ($M)
Current Assets 68.33
Assets 68.77
Liabilities 4.59
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -22.49
Net Income -21.75
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -19.40
Cash from Investing -0.18
Cash from Financing 68.03

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
7 days ago 13G/A Franklin Resources Inc
12-06 13G/A Janus Henderson Group Plc 11.60 207.17
11-18 13D/A Suvretta Capital Management, Llc 49.90 62.30
11-14 13G Nantahala Capital Management, LLC
11-13 13G/A HBM Healthcare Investments (Cayman) Ltd. 9.70 22.56
04-11 13G/A Adage Capital Partners Gp, L.l.c. 9.99 39.81
02-14 13G/A Citadel Advisors Llc 3.60

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPO
2024-09-26 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended June 30, 2024 ☐ Transition Report under Sect
2024-05-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT P
2024-02-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 ☐ TRANSITION REPOR

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-01-31 7,377 31,520 23.40
2025-01-30 1,882 18,135 10.38
2025-01-29 3,752 15,210 24.67
2025-01-28 1,262 11,484 10.99

(click for more detail)

Similar Companies
BGM – BGM Group Ltd. BIVI – BioVie Inc.
BMRA – Biomerica, Inc. BOLT – Bolt Biotherapeutics, Inc.
BON – Bon Natural Life Limited


Financial data and stock pages provided by
Fintel.io